TY - JOUR
T1 - Marine ω-3 polyunsaturated fatty acids and risk for colorectal cancer according to microsatellite instability
AU - Song, Mingyang
AU - Nishihara, Reiko
AU - Wu, Kana
AU - Qian, Zhi Rong
AU - Kim, Sun A.
AU - Sukawa, Yasutaka
AU - Mima, Kosuke
AU - Inamura, Kentaro
AU - Masuda, Atsuhiro
AU - Yang, Juhong
AU - Fuchs, Charles S.
AU - Giovannucci, Edward L.
AU - Ogino, Shuji
AU - Chan, Andrew T.
N1 - Publisher Copyright:
© 2015 The Author. Published by Oxford University Press. All rights reserved.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Background: Chronic inflammation is involved in the development of colorectal cancer (CRC) and microsatellite instability (MSI), a distinct phenotype of CRC. Experimental evidence indicates an anti-inflammatory and antineoplastic effect of marine ω-3 polyunsaturated fatty acids (PUFAs). However, epidemiologic data remain inconclusive. Methods: We investigated whether the association between marine ω-3 PUFAs and CRC varies by MSI-defined subtypes of tumors in the Nurses' Health Study and Health Professionals Follow-up Study. We documented and classified 1125 CRC cases into either MSI-high tumors, in which 30% or more of the 10 microsatellite markers demonstrated instability, or microsatellite-stable (MSS) tumors. Cox proportional hazards model was used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) of MSS tumors and MSI-high tumors in relation to marine ω-3 PUFA intake. All statistical tests were two-sided. Results: Marine ω-3 PUFA intake was not associated with overall incidence of CRC. However, a statistically significant difference was detected by MSI status (P heterogeneity =. 02): High marine ω-3 PUFA intake was associated with a lower risk for MSI-high tumors (comparing 0.30g/d with <0.10g/d: multivariable HR = 0.54, 95% CI = 0.35 to 0.83, P linearity =. 03) but not MSS tumors (HR = 0.97, 95% CI = 0.78 to 1.20, P linearity =. 28). This differential association appeared to be independent of CpG island methylator phenotype and BRAF mutation status. Conclusions: High marine ω-3 PUFA intake is associated with lower risk for MSI-high CRC but not MSS tumors, suggesting a potential role of ω-3 PUFAs in protection against CRC through DNA mismatch repair. Further research is needed to confirm our findings and elucidate potential underlying mechanisms.
AB - Background: Chronic inflammation is involved in the development of colorectal cancer (CRC) and microsatellite instability (MSI), a distinct phenotype of CRC. Experimental evidence indicates an anti-inflammatory and antineoplastic effect of marine ω-3 polyunsaturated fatty acids (PUFAs). However, epidemiologic data remain inconclusive. Methods: We investigated whether the association between marine ω-3 PUFAs and CRC varies by MSI-defined subtypes of tumors in the Nurses' Health Study and Health Professionals Follow-up Study. We documented and classified 1125 CRC cases into either MSI-high tumors, in which 30% or more of the 10 microsatellite markers demonstrated instability, or microsatellite-stable (MSS) tumors. Cox proportional hazards model was used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) of MSS tumors and MSI-high tumors in relation to marine ω-3 PUFA intake. All statistical tests were two-sided. Results: Marine ω-3 PUFA intake was not associated with overall incidence of CRC. However, a statistically significant difference was detected by MSI status (P heterogeneity =. 02): High marine ω-3 PUFA intake was associated with a lower risk for MSI-high tumors (comparing 0.30g/d with <0.10g/d: multivariable HR = 0.54, 95% CI = 0.35 to 0.83, P linearity =. 03) but not MSS tumors (HR = 0.97, 95% CI = 0.78 to 1.20, P linearity =. 28). This differential association appeared to be independent of CpG island methylator phenotype and BRAF mutation status. Conclusions: High marine ω-3 PUFA intake is associated with lower risk for MSI-high CRC but not MSS tumors, suggesting a potential role of ω-3 PUFAs in protection against CRC through DNA mismatch repair. Further research is needed to confirm our findings and elucidate potential underlying mechanisms.
UR - http://www.scopus.com/inward/record.url?scp=84930690119&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930690119&partnerID=8YFLogxK
U2 - 10.1093/jnci/djv007
DO - 10.1093/jnci/djv007
M3 - Article
C2 - 25810492
AN - SCOPUS:84930690119
SN - 0027-8874
VL - 107
JO - Cancer chemotherapy reports. Part 1
JF - Cancer chemotherapy reports. Part 1
IS - 4
ER -